Speciality: ENT
Description:
A warm welcome to all the medical professionals in this interesting session on Allegra M: The number 1 prescribed Fexofenadine-Montelukast (FM) brand in India.
Allegra M has emerged as the number one prescribed brand of Fexofenadine-Montelukast (FM) in India. This combination medication is widely recognized for its efficacy in managing allergic rhinitis and asthma, providing relief from symptoms like sneezing, runny nose, and wheezing. The brand's leading position underscores its popularity and trust among healthcare professionals and patients alike.
Allegra M combines Fexofenadine, a potent antihistamine, with Montelukast, a leukotriene receptor antagonist. This dual-action formula addresses multiple pathways involved in allergic reactions, making it highly effective for patients with co-existing respiratory conditions. By targeting both histamines and leukotrienes, Allegra M offers comprehensive symptom control, enhancing patient quality of life.
The widespread prescription of Allegra M reflects its clinical benefits, including rapid onset of action and sustained symptom relief. Patients report significant improvement in nasal congestion, sneezing, and bronchoconstriction, leading to better disease management and fewer exacerbations. Its well-tolerated profile also contributes to high patient adherence and satisfaction.
Therefore, get an overall knowledge of allegra M: The number 1 prescribed fexofenadine-montelukast (FM) brand in India.
See More Webinars @ Hidoc Webinars
1.
Physician Fights Insurer to Cover Her Baby's Brain Cancer Treatment
2.
A small rise in cancer was observed following the 1986 Chernobyl accident.
3.
First-Line Combination for Bladder Cancer Not Eligible for Cisplatin Just Misses Positive Outcome.
4.
New research uncovers link between cancer pathway and blood-retina barrier function
5.
Standardized criteria for amino acid PET imaging could improve diagnosis and treatment of brain metastases
1.
Bispecific Antibodies in DLBCL & Myeloma: Clinical Insights for Physicians
2.
Survivorship Planning Beyond Active Cancer Care
3.
Understanding Blood Dyscrasia: Symptoms, Causes and Treatment Options
4.
Integrated Models in Hematology for Specialists
5.
Matrix Metalloproteinases in Stroke: Broad vs. Selective Inhibition Strategies
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Targeting Oncologic Drivers with Dacomitinib: A New Approach to Lung Cancer Treatment
2.
Pazopanib Takes Center Stage in Managing Renal Cell Carcinoma - Part I
3.
An Eagles View - Evidence-based discussion on Iron Deficiency Anemia- Further Talks
4.
Role of Nimotuzumab in Management of Nasopharyngeal Cancer
5.
Lorlatinib in the Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update)
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation